• 2016

     
    US-FDA approval received for Baddi

     
    Pharmexcil Patent Award “NEW CHEMICAL ENTITIES (NCEs) – SILVER AWARD 2015-2016”.
  • 2014

     
    US-FDA renewal received for Waluj

     
    PICS approval received for Waluj
  • 2013

     
    UK-MHRA renewal received for Waluj

     
    US-FDA renewal received for Roha

     
    IDMA Margi Memorial Best Patent Award for “BEST NEW CHEMICAL ENTITY PATENT AWARD 2012-13”

     
    Pharmexcil Patent Award “NEW CHEMICAL ENTITIES (NCEs) – SILVER AWARD 2012-2013”
  • 2012

     
    UK-MHRA renewal received for Goa Plants - I, II & III

     
    US-FDA renewal received for Waluj

     
    Pharmexcil CERTIFICATE OF APPRECIATION PATENT AWARD 2011-2012, in recognition of commendable contribution in Bulk Drugs Category
  • 2011

     
    Pharmexcil CERTIFICATE OF APPRECIATION PATENT AWARD 2010-2011, in recognition of commendable contribution in Bulk Drugs Category
  • 2009

     
    UK-MHRA approval received for Goa units - I, II & III
  • 2008

     
    US-ANDA approval received for three ophthalmic formulations

     
    US-FDA approval received for Waluj

     
    MHRA approval received for Goa unit - I

     
    New oral Cephalosporins facility set-up at Baddi
  • 2006

     
    Forbes rates FDC among the "BEST UNDER A BILLION COMPANIES"

     
    US Patent awarded for UV-Lube, the first definitive therapy for dry-eye syndrome
  • 2005

     
    First US-FDA approval for ophthalmic facility at Waluj

     
    2 ANDAs filed for ophthalmic dosage forms in the U.S.
  • 2004

     
    FDC South Africa established
  • 2002

     
    First UK-MHRA approval for oral solids facility at Goa Plant - I
  • 1999

     
    FDC International set-up in the UK for distribution and marketing of Ophthalmic products
  • 1998

     
    UK-MHRA approval for ophthalmic facility at Waluj
  • 1996

     
    Public issue of 26,28,200 equity shares of Rs. 10 each at a premium of Rs. 90 each

     
    FDC awarded 'Export House' status

     
    Specialized & dedicated field force established to promote ophthalmic specialties
  • 1994

     
    First Indian company to introduce BFS (Blow-Fill-Seal) technology in Ophthalmics, which optimizes sterility and is highly user friendly
  • 1992

     
    National Award from the Council of Scientific Research and Industry (CSRI) for Indigenous R&D of Flurbiprofen and Timolol Maleate
  • 1991

     
    Biotechnology research centre set-up at Waluj

     
    Production of Timolol Maleate (API) started
  • 1989

     
    Started commercial production of Flurbiprofen
  • 1987

     
    Multi-purpose formulation plant commissioned at Waluj in Maharashtra
  • 1986

     
    Fairdeal Corporation (Pvt.) Ltd. was renamed FDC Private Limited
  • 1985

     
    First US FDA approval of API plant at Roha
  • 1984

     
    Foods division set up for manufacture of specialized infant foods at Roha
  • 1977

     
    Active Pharmaceutical Ingredient (API) plant commissioned at Roha, Maharashtra
  • 1974

     
    Fairdeal's R&D facilities obtain recognition from Government of India
  • 1972

     
    Introduced Electral - a result of pioneering work in Oral Rehydration Therapy
  • 1963

     
    Introduced Vanmycetin Eye Drops - starting point for ophthalmic and ENT range
  • 1949

     
    Formulation plant established in Jogeshwari, Mumbai
  • 1940

     
    The Fairdeal Corporation was incorporated as a Fairdeal Corporation (Private) Limited Company under Indian Companies Act, 1913
  • 1936

     
    Mr. Anand Chandavarkar set-up Fairdeal Corporation (FDC) to import drugs, infant foods and surgical appliances for distribution in India